The Pharmaletter

One To Watch

pdclinepharma_company_logo

PDC*Line Pharma

A clinical-stage biotech developing a new class of potent and scalable active immunotherapies for cancer.

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells.

PDC*line is more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors.

Want to Update your Company's Profile?


More PDC*Line Pharma news >